Close

Anti-NY-ESO-1 (SLIMWITQC) TCR-Like CAR [scFv (T1)-BBζ], HLA-A*0201-Restricted (TLA-CA-273PZ)


All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

The chimeric antigen receptors (CARs) have emerged as a useful tool to redirect T cells. However, despite very potent, CAR is limited to recognize membrane proteins which only comprise around 1% of the total proteins. There are plenty of attractive tumor antigens arising from intracellular proteins. TCR-like antibodies, which allow for specific targeting of intracellular proteins via MHC/peptide complexes, appear as an unexploited opportunity for antibody therapies. Therefore, introduction of an antigen-binding fragment from TCR-like antibody to CAR, termed TCR-like CAR, will breakthrough the antigen limitation of CAR and combines the benefits of both. Our TCR-like CAR opens therapeutic avenues not only conserving the specificity and the functionality of the original TCR-like antibody, but also performing T cell signaling for cellular functions.

Specific Inquiry

  • Size:
  • Marker:
  • Form:
  Add to Cart

DESCRIPTION

  • Target
  • NY-ESO-1
  • Targeting Cell Type
  • Tumor Cell
  • Receptor Construction
  • scFv-4-1BB-CD3ζ
  • Discription of Signaling Cassetes
  • 4-1BB
    CD137 (also known as 4-1BB) is a surface co-stimulatory glycoprotein originally described as present on activated T lymphocytes, which belongs to the tumor necrosis factor (TNF) receptor superfamily. It is expressed mainly on activated CD4+ and CD8+ T cells, and binds to a high-affinity ligand (4-1BBL) expressed on several antigen-presenting cells such as macrophages and activated B cells. On the basis of preclinical observation, this molecule can promote the persistence of antigen-specific and antigennonspecific chimeric antigen receptor T-cells to significantly increases antitumor activity.
    CD3ζ
    CD3ζ, also known as T-cell receptor zeta, which together with T-cell receptor and CD3γ, δ , ε chain, forms the TCR-CD3 complex. ζ was expressed independently from the complex. The zeta chain plays an important role in coupling antigen recognition to several intracellular signal-transduction pathways. CD3-zeta, which contains 3 ITAMs, is the most commonly used endodomain component of CARs. It transmits an activation signal to the T cell after antigen is bound. CD3-zeta may not provide a fully competent activation signal and additional co-stimulatory signaling is needed. For example, chimeric CD28 and OX40 can be used with CD3-zeta to transmit a proliferative/survival signal, or all three can be used together.
  • Vector Name
  • pCDCAR1
  • Vector Type
  • Lentiviral vector
  • Format
  • scFv
  • Epitope
  • SLIMWITQC
  • HLA
  • HLA-A*0201
  • Targeting Diseases
  • scFv-4-1BB-CD3ζ

BACKGROUND

  • Clone
  • T1
  • Host
  • Human
  • Target Species
  • Human
  • Synonyms
  • CTAG; ESO1; CT6.1; CTAG1; LAGE-2; LAGE2B; NY-ESO-1

Customer Reviews and Q&As

There are currently no customer reviews or questions for Anti-NY-ESO-1 (SLIMWITQC) TCR-Like CAR [scFv (T1)-BBζ], HLA-A*0201-Restricted (TLA-CA-273PZ). Click the button below to contact us or submit your feedback about this product.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Related Products

Online Inquiry

For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.